Brand Watch: Three companies put their impacts on nature under a microscope. Here’s what they found
Look deep into nature and then you will understand everything better.” The quote from Albert Einstein is generally deployed ...
Barclays Remains a Hold on GlaxoSmithKline (GSK)
In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...
GSK to buy US biotech firm IDRx for up to $1.15 billion
(Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour. IDRx, ...
FierceBiotech4d
GSK, Merck and Pfizer in Ab&B's sights as Chinese vaccine biotech files for IPO
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
GSK Enters Agreement to Acquire IDRx, Inc.
GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company ...
MercoPress2d
GSK to open distribution hub in Montevideo
Lacalle Pou “welcomed GSK's announcement of the opening of one ... delivery times through a hub where it will concentrate the products manufactured in its different plants in Europe.
GlaxoSmithKline: Sell Rating Amidst Weak Vaccine Performance and Projected EPS Decline
GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...